Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × lifileucel × Dermatologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Ipilimumab 82 pembrolizumab 79 Nivolumab 73 Cyclophosphamide 62 fludarabine phosphate 51 aldesleukin 47 Interleukin-2 34 Dacarbazine 31 fludarabine 29 Vemurafenib 29 trametinib 26 dabrafenib 25 Temozolomide 23 Aminolevulinic Acid 19 Whole-Body Irradiation 18 Radiosurgery 17 Bevacizumab 17 Peripheral Blood Stem Cell Transplantation 16 Carboplatin 16 3-ingenyl angelate 16 Radiotherapy 15 Mycophenolic Acid 15 HhAntag691 14 Tacrolimus 13 Paclitaxel 13 Introns 13 Interferon alpha-2 13 Cyclosporine 13 CTLA-4 Antigen 13 Antilymphocyte Serum 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02360579 2025-12-09

LN-144

Iovance Biotherapeutics, Inc.

Phase 2 Completed

220 enrolled 15 charts 1 FDA

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡